Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Oligodendroglioma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 59 Breast Neoplasms 18 Prostatic Neoplasms 14 Neoplasms 14 Fallopian Tube Neoplasms 13 Neoplasm Metastasis 8 Pancreatic Neoplasms 7 Glioblastoma 7 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 5 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Recurrence 3 Melanoma 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Mesothelioma, Malignant 2 Mesothelioma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2

Interventions

Temozolomide 65 Radiotherapy 29 Carboplatin 19 Bevacizumab 17 Carmustine 15 Irinotecan 13 Filgrastim 13 Vincristine 12 Magnetic Resonance Spectroscopy 12 Surgical Procedures, Operative 10 Procarbazine 10 Peripheral Blood Stem Cell Transplantation 7 Lomustine 7 Etoposide 7 Cyclophosphamide 7 O(6)-benzylguanine 6 Imatinib Mesylate 6 Flucytosine 6 Erlotinib Hydrochloride 6 sargramostim 5 Thiotepa 5 Radiotherapy, Intensity-Modulated 5 Radiation 5 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5 vocimagene amiretrorepvec 4 temsirolimus 4 Immunohistochemistry 4 Cisplatin 4 Chemotherapy, Adjuvant 4 Biopsy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05297864 2025-05-23

OU-SCC-PI-4G

University of Oklahoma

Phase 2 Terminated

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡